Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status

RMD Open 2024;10:e003884 doi: 10.1136/rmdopen-2023-003884 https://pubmed.ncbi.nlm.nih.gov/38724259/

The safety follow-up extension of the C-axSpAnd trial showed that long-term clinical outcomes from certolizumab pegol treatment achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups.

Rudwaleit, et al. randomised patients with nr-axSpA 1:1 to certolizumab pegol 200mg Q2W or placebo in the 52-week double-blind period. At Week 52, the optional safety follow-up extension treated all patients with open-label certolizumab pegol through 156 weeks.